制造商和分销商
默沙东有限公司
销售
杏林製薬株式会社 注:以上中文处方资料不够完整,使用者以原处方资料为准。
完整说明资料附件: https://www.info.pmda.go.jp/go/pack/2290001F1028_1_02/2290001F1028_1_02?view=body&lang=ja
---------------------------------------------
Innovative drug for chronic cough! New drug Lyfnua(gefapixant)approved in Japan: global selective P2X3 receptor antagonist, significantly reducing cough frequency
On January 24, 2022, the new cough medicine Lyfnua(gefapixant, MK-7264)45mg tablet was approved in Japan: the medicine is an oral, selective P2X3 receptor antagonist for the treatment of refractory chronic cough in adults (RCC) or unexplained chronic cough (UCC).
RCC refers to cough that persists despite appropriate treatment for the underlying disease, and UCC refers to cough in which the underlying cause cannot be identified despite thorough eva luation. For medication, Lyfnua 45mg tablets are taken twice a day.
It is worth mentioning that Lyfnua is the world's first approved selective P2X3 receptor antagonist and the first drug specifically for the treatment of RCC and UCC. Lyfnua inhibits extracellular ATP signaling through P2X3 receptors present on airway vagal C fibers and reduces sensory nerve activation and cough.